ALK37-005: A Study of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)

Phase 2 Completed 157 enrolled Alkermes, Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability and efficacy of ALKS 37 when administered daily for 4 weeks to adults with Opioid-induced Constipation (OIC).

Timeline

Start: 2011-08
Primary completion: 2012-04
Completion: 2012-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	METHYLSAMIDORPHAN	Small molecule	—	Oral

ALK37-005: A Study of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)

Summary

Timeline

Drugs

Indications